Biosimilars for Tremfya: Are Any Available in 2026?

There are no FDA-approved biosimilars for Tremfya in the United States as of August 10, 2026. The FDA's current list contains no product referencing Tremfya or its active ingredient, guselkumab. That direct answer matters because search results can mix together biosimilars, other drugs in the same treatment class, and different Tremfya formulations. Those categories have distinct regulatory and insurance consequences.

Are any biosimilars for Tremfya available?

The FDA Purple Book identifies Tremfya as a 351(a) reference biologic with guselkumab as its proper name and Janssen Biotech as its applicant. A biosimilar referencing Tremfya would appear as a separate 351(k) product after FDA approval. The Purple Book currently displays Tremfya presentations and no corresponding guselkumab biosimilar.

Tremfya also has no generic version. The FDA patient guide explains that biologics are made from living sources and are evaluated through the biosimilar pathway, while conventional generics generally copy smaller, simpler chemical drugs. A medicine that targets the same inflammatory pathway can be a treatment alternative, yet it becomes a Tremfya biosimilar only after FDA compares it with Tremfya and approves it on that basis.

What Tremfya is and how IBD dosing works

Tremfya is guselkumab, an interleukin-23 antagonist. The current prescribing information covers adults with moderately to severely active ulcerative colitis or Crohn's disease and includes intravenous and subcutaneous presentations. The specific induction and maintenance schedule depends on the IBD indication and regimen selected by the prescriber, so the product label and current prescription should guide dose verification.

The phase 3 QUASAR studies evaluated intravenous guselkumab induction followed by subcutaneous maintenance in adults with moderately to severely active ulcerative colitis. That evidence concerns Tremfya itself. It does not establish biosimilarity for another product because FDA biosimilar approval requires a manufacturer to submit a comparison package for a proposed product and its named reference biologic.

What patients may mistake for a Tremfya biosimilar

Other interleukin-23 medicines are separate active ingredients with their own FDA applications, labels, doses, devices, and approved uses. A clinician may consider one of them as an alternative therapy, while that type of change is a switch between different drugs. A biosimilar switch keeps the same reference-product relationship established through FDA's 351(k) pathway. The FDA review overview defines a biosimilar as highly similar to its reference product with no clinically meaningful differences in safety, purity, or potency.

The route can create another source of confusion. Receiving Tremfya by infusion during induction and by injection during maintenance is a change in presentation within the branded treatment plan described in the Tremfya label. It is not evidence that a biosimilar was dispensed. Check the brand, active ingredient, strength, route, and nonproprietary suffix on every new order or shipment.

Insurance implications while no biosimilar exists

Without an approved Tremfya biosimilar, an insurer cannot select a guselkumab biosimilar as a direct substitute. A plan can still apply prior authorization, preferred-treatment requirements, site-of-care rules, specialty-pharmacy restrictions, or a request to use another therapy. The Crohn's & Colitis Foundation biosimilar guide recommends confirming the exact covered product, effective date, supply source, patient cost, and appeal options whenever coverage changes.

Intravenous doses may run through the medical benefit, while self-administered doses may run through the pharmacy benefit. CMS publishes Part B drug payment information for clinician-administered biological products, and commercial benefit design varies by plan. Ask the insurer to confirm both phases in writing, including the authorized provider, specialty pharmacy, approval dates, deductible, copay, and coinsurance.

How to check for a future Tremfya biosimilar

Use the live FDA biosimilar product list for approvals and the Purple Book Tremfya record for licensed product relationships and presentations. Company announcements, clinical trials, and foreign approvals can indicate development activity. U.S. status begins with FDA approval. A future FDA entry should provide a proprietary name, a guselkumab suffix, an applicant, an approval date, and a reference to Tremfya.

When a plan or pharmacy uses the word "biosimilar," request the exact product name and verify it in those FDA databases. As of August 10, 2026, the accurate search answer remains simple: Tremfya has no FDA-approved biosimilar in the United States. Coverage changes involving another active ingredient should be evaluated as a change in therapy with the prescribing gastroenterologist.

Save a screenshot or PDF of any coverage notice and note the date it was received. Ask whether the notice changes the active ingredient, the Tremfya presentation, the dispensing pharmacy, or only the authorization process. Those four possibilities require different responses. Providing the exact notice to the care team prevents a broad term such as "alternative" from being mistaken for an approved guselkumab biosimilar.